Jump to navigation

  • Cochrane Library
  • Cochrane.org
  • Admin
Home

Cochrane
Hepato-Biliary

Trusted evidence.
Informed decisions.
Better health.

New Protocol published (year 2023)

Wang C, Kanaan G, Shang Y, Chai L, Li H, Qi X. Silymarin for treatment of adults with nonalcoholic fatty liver disease. Cochrane Database of Systematic Reviews 2023, Issue 4. Art. No.: CD015524. DOI: 10.1002/14651858.CD015524. Accessed 11 April 2023.

CHBG News

  • New Intervention Review published
  • A new checklist for developing and reporting the questions addressed in systematic reviews of interventions (the InSynQ checklist) recommended for Cochrane reviews
  • New Intervention Review published (year 2023)
  • New Protocol published (year 2023)
  •  
  • 1 of 19
  • next ›
More news

Latest News and Events

  • Cochrane at the 76th World Health Assembly
  • Cochrane seeks Head of Membership, Learning & Support - remote
  • Cochrane seeks Creative Content Producer - remote
  • Cochrane seeks Communication Officer - flexible, remote
  • Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes
More
  • Welcome
  • About us
  • Scope of work
  • Resources
  • Contact us
  • Join Cochrane
Cochrane
  • About Cochrane
    • Cochrane.org
    • Who we are
    • Get involved
    • Consumer Network
    • Partners
    • Colloquium
    • In the news
  • Publications
    • Cochrane Library
      • Cochrane Reviews (CDSR)
      • Trials (CENTRAL)
      • Cochrane Clinical Answers
    • Cochrane Evidence Synthesis and Methods
  • Community
    • Community
    • Cochrane Account
    • Training
    • Support
    • Methods
    • Software
    • Jobs and opportunities
    • Cochrane Store
  • Contact us
    • General enquiries
    • Cochrane Library support
    • Cochrane Groups
    • Media
RSS Twitter Facebook YouTube Instagram LinkedIn
Trusted evidence.
Informed decisions.
Better health.
Copyright © 2023 The Cochrane Collaboration
Disclaimer | Privacy | Cookie policy
We use cookies to improve your experience on our site. OK More information